
FDA Implements Updated iPLEDGE REMS Requirements for Isotretinoin
Key Takeaways
- Monthly pregnancy testing may occur outside medical settings after initial in-office testing, including at-home testing, contingent on prescriber procedures to mitigate misinterpretation or falsification risks.
- The prior requirement for an additional waiting period after missing the 7-day post-test pickup window is removed; immediate repeat testing is permitted, in-office if pre-treatment.
FDA implements updated iPLEDGE REMS requirements for isotretinoin, allowing at-home pregnancy testing and reducing prescription and counseling burdens.
The US Food and Drug Administration (FDA) announced the implementation of the updated requirements for isotretinoin, which is approved to treat
Expanded Flexibility for Pregnancy Testing
Among the most significant changes is increased flexibility surrounding pregnancy testing. Patients who can become pregnant must still complete the required pregnancy tests in a medical setting before initiating treatment. However, prescribers may now permit subsequent monthly pregnancy tests to be conducted outside a medical setting, including through at-home testing, during and after treatment.
Prescribers who allow at-home testing must establish procedures to minimize the risk of test misinterpretation or falsification.
The updated program also eliminates the additional waiting period previously required when patients who can become pregnant failed to obtain their isotretinoin prescription within 7 days of a negative pregnancy test. These patients may now repeat pregnancy testing immediately. For patients who have not yet initiated treatment, the repeat test must be performed in a medical setting.
Reduced Counseling and Prescription Requirements
Additional modifications streamline counseling and
The FDA also eliminated the 30-day prescription window for patients who cannot become pregnant. Pharmacies must ensure that unused prescription authorizations are reversed in the REMS system and medications returned to stock when prescriptions are not picked up.
Existing Enrollment and Certification Requirements Remain
Existing patients, prescribers, and pharmacy representatives
The changes are intended to improve access to isotretinoin and reduce
Additional guidance is available through the
References
- US Food and Drug Administration. iPLEDGE Risk Evaluation and Mitigation Strategy (REMS). Updated June 16, 2026. Accessed November 16, 2026.
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems - US Food and Drug Administration. Questions and Answers on the iPLEDGE REMS. Accessed November 16, 2026.
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-ipledge-rems - US Food and Drug Administration. Isotretinoin Capsule Information. Accessed November 16, 2026.
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/isotretinoin-capsule-information
Related to this article








